AI-assisted international press reviewPress review

Bayer Unveils Promising Results from REVEAL Study on Cardiac Amyloidosis

At the 2026 Congress of the European Society of Cardiology, Bayer revealed the results of the REVEAL study, demonstrating that the radiotracer I 124 evuzamitide achieves high levels of sensitivity and specificity for diagnosing cardiac amyloidosis, marking a significant advancement in the fight against this complex disease. The results, published simultaneously in JAMA, underscore the importance of accurate diagnostics to enhance patient care.

Source: Bayer, published under the title "Phase III REVEAL Study with Investigational PET Radiotracer ..." - 30 August 2026

AskBio Unveils Key Features of Gene Therapy Trial for Heart Failure

At the European Society of Cardiology Congress, AskBio revealed the core features of the GenePHIT trial, one of the largest gene therapy trials for heart failure, involving over 170 participants across 12 countries. Results on the efficacy of umiposgene parvec (AB-1002) are expected by 2027, marking a significant advancement in the treatment of this complex disease.

Source: Bayer, published under the title "AskBio Presents Baseline Characteristics from Phase 2 Heart ..." - 30 August 2026

Bayer Seeks Approval to Expand Kerendia Use for CKD in Japan

Bayer has submitted a request for authorization in Japan to expand the use of finerenone, supported by positive results from the FIND-CKD study. This study demonstrated that finerenone slows the progression of non-diabetic chronic kidney disease (CKD), a major public health issue affecting nearly 20 million adults in Japan. Already approved for CKD associated with type 2 diabetes, finerenone could provide new therapeutic options for patients at high risk of cardiovascular complications.

Source: Bayer, published under the title "Bayer submits application in Japan for expanded use of Keren..." - 28 August 2026

Abbott Receives CE Mark for Amulet 360™ Device to Prevent Stroke

Abbott's Amulet 360™ device, designed to seal the left atrial appendage, has received CE marking, allowing its use in Europe. This next-generation device enhances the safety and efficacy of treatment for patients with atrial fibrillation, thereby reducing the need for anticoagulant medications. Promising clinical results support its adoption in medical practices, reinforcing Abbott's commitment to innovation in cardiology.

Source: Abbott, published under the title "Abbott's Next-Generation Amulet 360™ Device Receives CE Mark..." - 28 August 2026

Tezspire Shows Promising Phase III Results for Eosinophilic Esophagitis

The CROSSING trial reveals that Tezspire, a monoclonal antibody, significantly improves symptoms of eosinophilic esophagitis, a chronic inflammatory disease affecting thousands of patients. The results, sustained over 52 weeks, pave the way for new therapeutic options for this often challenging condition to treat.

Source: Astrazeneca, published under the title "Tezspire demonstrates positive Phase III results in eosinoph..." - 27 August 2026

Novartis: Harnessing AI for Large-Scale Research and Development

In a context where innovation is crucial, Novartis is integrating artificial intelligence to optimize its research and development processes. This approach aims to transform traditional methods by leveraging big data and advanced algorithms, thereby accelerating the discovery of new active ingredients and improving the efficiency of clinical trials. By adopting these technologies, Novartis positions itself at the forefront of biopharmacy while addressing the growing challenges of the pharmaceutical industry.

Source: Novartis, published under the title "Smarter decisions at scale: How Novartis is using AI to adva..." - 27 August 2026

Abbott Launches First Dual Glucose-Ketone Sensor for Diabetics

The recently FDA-approved Libre Duo 10 Day is a revolutionary biowearable device that simultaneously monitors glucose and ketone levels, enabling early detection of diabetic ketoacidosis risks. Designed to ease daily diabetes management, it integrates with the Libre digital ecosystem and automated insulin delivery systems, providing a comprehensive solution for patients. This innovation could transform diabetes care by offering early alerts and real-time data on their health status.

Source: Abbott, published under the title "Abbott Receives FDA Authorization For World's First Dual Glu..." - 26 August 2026

IMAAVY: First Approved Treatment for Warm Autoimmune Hemolytic Anemia

Johnson & Johnson announces FDA approval of IMAAVY, marking a major advancement in the treatment of warm autoimmune hemolytic anemia (wAIHA). This innovative treatment targets pathogenic IgG autoantibodies, providing an alternative to traditional therapies, and has shown significant efficacy in the ENERGY clinical study. Patients can now benefit from a therapeutic option specifically designed for their condition, thereby improving their quality of life.

Source: J&j - 25 August 2026

Approval of Sevabertinib in Japan for HER2-Mutant Lung Cancer

Sevabertinib, the first targeted therapy approved in Japan for non-small cell lung cancer with HER2 mutation, offers a promising new treatment option. Based on the results of the SOHO-01 trial, it demonstrates significant efficacy and a manageable safety profile, addressing an urgent medical need for these patients.

Source: Bayer, published under the title "Bayer’s sevabertinib approved in Japan for patients with HER..." - 24 August 2026

Hibsago: First Functional Treatment for Chronic Hepatitis B Approved in Japan

Japan has approved Hibsago (bepirovirsen), marking a significant advancement in the treatment of chronic hepatitis B, with a functional cure rate of 19% after 6 months of treatment. This approval, supported by clinical trials, could transform the management of this disease affecting nearly one million people in the country.

Source: Gsk, published under the title "Hibsago (bepirovirsen) approved in Japan as first and only f..." - 24 August 2026

FDA Prioritizes Review of Jemperli for Innovative Rectal Cancer Treatment

The FDA has accepted Jemperli's application for the treatment of advanced dMMR/MSI-H rectal cancer, backed by promising data from the AZUR-1 trial. If approved, this treatment could revolutionize the management of this disease by eliminating the need for chemotherapy, radiotherapy, and surgery for certain patients. This initiative is part of the Orbis project, aimed at accelerating international approvals.

Source: Gsk, published under the title "Jemperli (dostarlimab) accepted for priority review by the U..." - 24 August 2026

Johnson & Johnson Launches Surgical Outcomes Classification System

The recently published DISH Classification System establishes a standardized framework for measuring and reporting surgical complications, aiming to enhance the quality of care and reduce post-operative readmissions. Developed by international experts, this system provides a common language for evaluating outcomes, thereby facilitating the documentation and analysis of clinical practices.

Source: J&j - 24 August 2026

Abbott et Big Ten relancent "We Give Blood" face à la crise des dons de sang

La campagne "We Give Blood" unissant les universités de la Big Ten vise à remédier à la crise nationale des dons de sang, en incitant les jeunes à devenir des donneurs réguliers. Avec un million de dollars à la clé pour l'université ayant le plus de dons, Abbott et la Big Ten espèrent mobiliser la communauté étudiante et élargir la base de donneurs, alors que la majorité des dons proviennent actuellement de personnes âgées. Les dons peuvent être enregistrés à partir du 26 août, mais les contributions précoces sont encouragées dès le 12 août.

Source: Abbott, published under the title "Abbott And Big Ten Bring Back 'We Give Blood' As U.S. Faces ..." - 21 August 2026

L'Initiative NACHC et Abbott : La Nutrition au Cœur des Soins de Santé

L'initiative NACHC et Abbott, axée sur l'intégration de la nutrition dans les soins de santé primaires, propose un programme de certification et des ressources pour les centres de santé communautaires. En touchant plus de 1 500 CHCs, elle vise à améliorer l'accès à des aliments sains pour 52,3 millions de personnes, soulignant l'importance de la nutrition dans la prévention et la gestion des maladies chroniques.

Source: Abbott, published under the title "Abbott And NACHC Launch Nationwide Food For Health Initiativ..." - 21 August 2026

Novartis Strengthens Cardiovascular Leadership at ESC Congress 2026

At the 2026 European Society of Cardiology Congress, Novartis showcases key data from its cardiovascular portfolio, highlighting its commitment to therapeutic innovation for at-risk patients. The studies presented, particularly on Leqvio and Abelacimab, aim to enhance treatments and address ongoing challenges in cardiovascular care. This congress serves as a vital platform for sharing scientific advancements and fostering collaboration in cardiology.

Source: Novartis, published under the title "Novartis data at ESC Congress 2026 reinforce cardiovascular ..." - 19 August 2026

Amélioration de la santé des diabétiques grâce au programme Healthy Food Rx d'Abbott

Une étude présentée lors des sessions scientifiques de l'ADA révèle que le programme Healthy Food Rx d'Abbott, qui fournit des boîtes alimentaires saines et un coaching communautaire, entraîne des améliorations significatives dans la gestion du diabète, la qualité de l'alimentation et la santé physique et mentale des participants. Les résultats soulignent l'importance d'une approche centrée sur la communauté pour améliorer les résultats de santé des personnes vivant avec le diabète.

Source: Abbott, published under the title "New Research Shows Even Stronger Health Outcomes For Partici..." - 18 August 2026

Partenariat innovant entre Abbott et Google Health pour la santé métabolique

Abbott et Google Health annoncent un partenariat inédit visant à transformer la gestion de la santé quotidienne grâce à des insights sur le glucose. En intégrant les données du moniteur de glucose Lingo d'Abbott dans l'application Google Health, les utilisateurs bénéficieront d'une vue d'ensemble de leur santé métabolique. Ce projet inclut une étude de grande envergure pour mieux comprendre les liens entre les habitudes de vie et la santé, avec l'objectif de prévenir les maladies métaboliques croissantes, telles que le diabète de type 2.

Source: Abbott, published under the title "Abbott And Google Launch First-Of-Its-Kind Partnership To Tr..." - 18 August 2026

Abbott et Big Ten relancent "We Give Blood" face à la crise des dons de sang

La campagne "We Give Blood" unissant les universités de la Big Ten vise à remédier à la crise nationale des dons de sang, avec des incitations pour encourager les jeunes à s'engager dans le don. Alors que la demande de transfusions sanguines augmente, Abbott et la Big Ten espèrent mobiliser une nouvelle génération de donneurs pour assurer un approvisionnement durable en sang, crucial pour les patients nécessitant des transfusions.

Source: Abbott, published under the title "Abbott And Big Ten Bring Back 'We Give Blood' As U.S. Faces ..." - 18 August 2026

Abbott annonce son 410ème dividende trimestriel consécutif

Le conseil d'administration d'Abbott a déclaré un dividende trimestriel de 63 cents par action, marquant une continuité impressionnante de 410 dividendes consécutifs depuis 1924. Ce dividende, qui sera versé le 17 août 2026, témoigne de la solidité financière de l'entreprise, qui a augmenté ses paiements de dividendes pendant 54 années consécutives, la plaçant parmi les entreprises les plus fiables en matière de retour sur investissement pour les actionnaires.

Source: Abbott, published under the title "Abbott Declares 410th Consecutive Quarterly Dividend" - 13 August 2026

Abbott et Google Health : Une collaboration innovante pour la santé métabolique

Abbott et Google Health annoncent un partenariat inédit visant à transformer la gestion de la santé quotidienne grâce à des insights sur la glycémie. En intégrant les données du Lingo, un moniteur de glucose continu, dans l'application Google Health, les utilisateurs bénéficieront d'une vue d'ensemble de leur santé. Ce projet inclut également une étude de grande envergure pour explorer les liens entre les habitudes quotidiennes et la santé métabolique, tout en fournissant des recommandations personnalisées via l'IA pour encourager des choix de vie plus sains.

Source: Abbott, published under the title "Abbott And Google Launch First-Of-Its-Kind Partnership To Tr..." - 12 August 2026